Trending Topics in Gastroenterology | GastroAGI

SIMBA Trial - GUT Jan 2026

The SIMBA Trial, as described in the provided context, was a triple-blind, randomised, controlled, superiority trial aimed at evaluating whether simvastatin could reduce the recurrence of pancreatitis in patients with recurrent acute pancreatitis (RAP) or acute-on-chronic flares in chronic pancreatitis (CP). The trial was conducted across 23 centres and included patients who had experienced at least two episodes of RAP or CP flares in the previous 12 months. ### Key Details and Findings from the SIMBA Trial: 1. **Objective**: The primary goal was to test the efficacy of simvastatin, a statin with anti-inflammatory properties, as a prophylactic treatment to prevent the recurrence of pancreatitis. 2. **Design**: - **Randomisation**: Patients were randomly assigned to receive either simvastatin or a placebo for 1 year. - **Blinding**: The trial was triple-blind, ensuring that patients, investigators, and statisticians were unaware of the treatment allocation. - **Primary Endpoint**: The recurrence of pancreatitis was the primary measure of the trial's success. 3. **Participants**: The target sample size was 144 patients, but due to slow recruitment, an interim analysis was conducted with 85 patients (42.1% women). 4. **Results**: - **Recurrence Rate**: - In the intention-to-treat analysis, no statistically significant difference was observed between the simvastatin group (46.2% recurrence) and the placebo group (44.4% recurrence). The odds ratio (OR) was 1.07 (95% CI 0.43 to 2.66; p=0.88). - In the per-protocol analysis, recurrence rates were 35.5% for simvastatin and 41.9% for placebo (OR 0.76, 95% CI 0.27 to 2.12; p=0.60). - **Time to Recurrence**: No significant differences were observed between the groups. - **Adverse Events**: Development of diabetes mellitus was more frequent in the simvastatin group (4 patients vs 0 patients in the placebo group; p=0.04). 5. **Conclusion**: - The trial did not demonstrate that simvastatin reduces the recurrence rate of pancreatitis. - The results may be underpowered due to the early termination of the study. - The observed association between statins (simvastatin) and new-onset diabetes mellitus warrants further investigation. 6. **Implications**: - While statins have anti-inflammatory properties, their role in preventing pancreatitis recurrence remains uncertain based on this trial. - The potential risk of new-onset diabetes mellitus in patients taking statins, particularly simvastatin, should be explored further in future studies. ### Note: The trial's results highlight the importance of adequately powered studies to draw definitive conclusions. Any further references to the SIMBA trial in publications, such as GUT in January 2026, may include additional analyses, follow-up studies, or insights based on the trial's findings.

Acute pancreatitis, DM and Gut Microbiota

Acute pancreatitis (AP) is a common inflammatory condition of the pancreas that often requires hospitalization. While the in-hospital mortality rate for AP has decreased significantly due to advancements in clinical management, postdischarge morbidity and mortality remain high. One of the significant postdischarge complications associated with AP is the development of diabetes mellitus (DM). Emerging evidence suggests that the gut microbiota plays a critical role in influencing both the severity of AP and the risk of developing DM after discharge. ### **Key Findings on Acute Pancreatitis, DM, and Gut Microbiota** #### **1. Gut Microbiota and Acute Pancreatitis** - The gut microbiota is the community of microorganisms residing in the gastrointestinal tract, which plays a crucial role in health and disease. - During an episode of AP, significant alterations in the gut microbiota (dysbiosis) are observed. These changes are associated with the severity of AP and clinical outcomes such as length of hospital stay and in-hospital mortality. - In severe AP, specific microbial species, such as short-chain fatty acid (SCFA) producers (e.g., *Parabacteroides distasonis*, *Enterocloster bolteae*, and *Lachnospiraceae* species), are over-represented, which may influence inflammation and recovery. #### **2. Postdischarge Complications of AP** - Patients recovering from AP are at risk for several long-term complications, including: - Recurrent acute pancreatitis (RAP) - Progression to chronic pancreatitis (CP) - Pancreatic exocrine insufficiency (PEI) - Development of diabetes mellitus (DM) - Pancreatic ductal adenocarcinoma (PDAC) - Postdischarge mortality rates in AP patients are significantly higher compared to the general population, particularly within the first 2 years after discharge. Cardiovascular events, sepsis, gastrointestinal malignancies, and cancer-related cachexia are common causes of death. #### **3. Diabetes Mellitus After Acute Pancreatitis** - DM is a frequent complication following AP, referred to as post-pancreatitis diabetes mellitus (PPDM). It is distinct from type 1 and type 2 diabetes and is associated with higher mortality and hospital readmission rates. - The development of DM post-AP is hypothesized to result from pancreatic damage, inflammation, and endocrine dysfunction caused by the initial episode of AP. #### **4. Role of Gut Microbiota in Predicting DM** - A recent study has shown that the composition of the gut microbiota at the time of hospital admission for AP is strongly associated with the risk of developing DM after discharge. - Using advanced genomic sequencing techniques (16S rRNA and metagenomics), researchers identified 11 differentially abundant microbial species in rectal swabs that were predictive of postdischarge DM. - Key findings include: - The gut microbiota at admission significantly differs between patients who later develop DM and those who do not. - A ridge regression model using these 11 microbial species achieved high predictive accuracy for postdischarge DM: - Area under the receiver operating characteristic curve (AUC): 94.8% in a matched cohort and 86.2% in the entire cohort. - Positive predictive value: 66.6% - Negative predictive value: 96% - Overall accuracy: 95% - This suggests that the gut microbiota could serve as a biomarker for identifying patients at high risk for developing DM after AP. #### **5. Clinical Implications** - The ability to predict postdischarge DM based on gut microbiota could transform the management of AP by enabling tailored surveillance and early interventions for high-risk patients. - Stratification of follow-up care based on microbial patterns may improve patient outcomes and reduce healthcare costs. - Understanding the role of specific gut bacteria and their metabolites in the pathogenesis of DM after AP could lead to the development of preventive strategies, such as: - Probiotics or prebiotics to restore healthy gut microbiota. - Dietary interventions to modulate microbial composition. - Targeted therapies to mitigate inflammation and pancreatic damage. ### **Conclusion** The connection between acute pancreatitis, diabetes mellitus, and gut microbiota represents a promising area of research with significant clinical implications. The gut microbiota at the time of AP admission not only correlates with disease severity but also serves as a powerful predictor of postdischarge complications, particularly DM. These findings pave the way for microbiota-based diagnostic tools and therapeutic strategies to improve the long-term outcomes of patients recovering from AP.

New-Onset Diabetes and Pancreatic Cancer

New-Onset Diabetes (NOD) and its link to Pancreatic Cancer, specifically Pancreatic Ductal Adenocarcinoma (PDAC), is an emerging area of medical research. Glycemically defined new-onset diabetes (GNOD) has been identified as a high-risk clinical state for PDAC. Below is a detailed explanation of the relationship between NOD and pancreatic cancer, based on the provided context: ### Key Findings and Insights: 1. **Increased Risk of PDAC After GNOD**: - GNOD is strongly associated with an increased short-term risk of developing PDAC. Prospective validation studies have confirmed that individuals with GNOD are at a significantly higher risk of PDAC compared to the general population. - Among 18,838 adults aged 50 years or older with GNOD, 82 cases of PDAC were diagnosed during follow-up. 2. **Incidence and Risk**: - The race-adjusted 3-year incidence of PDAC after GNOD was found to be 0.62%, which is substantially higher than the background population rates. - Different racial and ethnic groups exhibit varying levels of PDAC risk: - **Non-Hispanic White patients**: Highest 3-year PDAC incidence (0.84%) and standardized incidence ratio (SIR) of 6.4. - **Hispanic patients**: 3-year incidence of 0.40% and SIR of 4.2. - **African American patients**: 3-year incidence of 0.37% and SIR of 2.4. - **Asian/Pacific Islander patients**: Lowest absolute incidence (0.22%) but elevated SIR of 3.0. - These findings highlight significant racial and ethnic variations in PDAC risk following GNOD. 3. **Timing of PDAC Diagnosis**: - GNOD precedes clinical diagnosis of PDAC by an average interval of 8 months. - Over 60% of PDAC diagnoses occur within the first 12 months after GNOD onset. - Approximately 30% of PDAC cases are diagnosed within just 4 months of GNOD identification. - Nearly 80% of PDAC cases are diagnosed within 24 months of diabetes onset, emphasizing the narrow time window during which the risk is highest. 4. **Demographic Characteristics**: - The majority of PDAC cases occur in older adults, with a mean age of 71 years. - Men are disproportionately affected, accounting for 60% of PDAC diagnoses in the GNOD cohort. 5. **Active Surveillance and Early Detection**: - GNOD can be identified in real time through active surveillance of electronic health records and laboratory glycemic data. This approach may enable earlier identification of individuals at elevated risk for PDAC. - Understanding the biological mechanisms underlying diabetes in PDAC could help develop targeted early detection strategies for patients with new-onset glycemic abnormalities. 6. **Clinical Implications**: - GNOD represents a critical, time-limited window during which PDAC risk is at its peak. Early recognition of GNOD could improve outcomes by facilitating timely diagnostic evaluations for PDAC. - Since GNOD precedes PDAC diagnosis, healthcare providers should consider investigating pancreatic cancer in patients with unexplained new-onset diabetes, especially in older adults. ### Summary: New-onset diabetes (GNOD) is not only a metabolic condition but also a potential early indicator of pancreatic cancer, particularly PDAC. The short-term risk of PDAC following GNOD is significantly elevated, with racial and ethnic differences in incidence rates and risk levels. Active glycemic surveillance and early detection efforts are crucial to identifying individuals at high risk during the time-limited window when PDAC risk is highest. This research underscores the importance of integrating diabetes management with cancer screening protocols, especially for older adults and those with unexplained glycemic abnormalities.

High visceral adiposity and low skeletal muscle mass independently predict the development of acute cholecystitis in patients with gallstones: a retrospective cohort study

The retrospective cohort study you are referencing addresses the relationship between body composition and the risk of developing acute cholecystitis in patients with gallstones. The findings highlight that high visceral adiposity (excess visceral fat) and low skeletal muscle mass are independent predictors of acute cholecystitis, emphasizing the role of metabolic and inflammatory factors in disease progression. Below is a detailed breakdown of the study's key insights: ### 1. **Prediction Gap Addressed** - Traditional risk markers for acute cholecystitis, such as gallstone size or presence alone, are insufficient to predict which patients will progress to inflammation. This study shifts the focus to metabolic and body composition factors, providing a more comprehensive risk stratification. ### 2. **Limits of BMI** - Body mass index (BMI) is a crude measure of obesity and does not differentiate between types of body tissue (e.g., visceral fat, subcutaneous fat, muscle mass). Therefore, BMI alone cannot accurately predict susceptibility to acute cholecystitis. ### 3. **Role of Visceral Fat** - Visceral fat is metabolically active and contributes to a chronic pro-inflammatory state. This inflammatory priming makes the gallbladder more susceptible to exaggerated responses to triggers, such as gallstone obstruction, leading to acute cholecystitis. - Visceral fat is distinctly associated with disease risk, as opposed to subcutaneous fat, which does not have the same inflammatory properties. ### 4. **Importance of Sarcopenia (Low Skeletal Muscle Mass)** - Reduced skeletal muscle mass (sarcopenia) is not merely a marker of frailty but actively contributes to disease development. Muscle tissue plays a protective role by providing physiological resilience against inflammatory triggers. - Patients with low muscle mass may experience heightened vulnerability to metabolic and inflammatory complications, including acute cholecystitis. ### 5. **Independent Risk Factors** - Both high visceral fat and low skeletal muscle mass independently increase the likelihood of developing acute cholecystitis. These factors are not dependent on gender, gallstone size, or other traditional risk markers. ### 6. **Gallstones Alone Insufficient** - The study highlights that gallstones alone are not enough to cause acute cholecystitis. An adverse metabolic background, characterized by visceral adiposity and sarcopenia, is required to trigger the inflammatory process. ### 7. **Systemic Disease Concept** - Acute cholecystitis should be redefined as a metabolic-inflammatory complication rather than a localized biliary event. This systemic perspective broadens the understanding of the disease, linking it to underlying metabolic syndrome conditions such as hypertension and dyslipidemia. ### 8. **CT-Based Assessment** - Computed tomography (CT) imaging is a valuable tool for assessing body composition. It enables precise and reproducible measurement of visceral fat and skeletal muscle mass, which are critical for risk stratification. - The study emphasizes the use of body composition analysis at the L3 vertebral level, which is a validated standard for representing whole-body composition. ### 9. **Gender Independence** - The predictive value of visceral fat and muscle mass transcends sex-based differences. Men and women with unfavorable metabolic body composition phenotypes are equally at risk for acute cholecystitis. ### 10. **Preventive Medicine Potential** - Identifying patients with high visceral fat and low skeletal muscle mass early provides an opportunity for lifestyle interventions, such as tailored diet and exercise programs, to reduce the risk of disease progression. - These modifiable risk factors represent actionable targets for preventing acute cholecystitis in at-risk patients. ### 11. **Clinical Paradigm Shift** - The findings suggest a need to redefine acute cholecystitis as a metabolic-inflammatory complication rather than an isolated biliary obstruction caused by gallstones. This paradigm shift supports a more holistic approach to patient management, focusing on systemic health and body composition. ### 12. **Risk Stratification Tool** - CT-derived body composition analysis offers a practical and precise method to identify gallstone patients at high risk for acute cholecystitis. This tool can help clinicians prioritize closer monitoring and early intervention for these patients. ### 13. **Peripheral Monitoring Opportunity** - Patients identified with unfavorable body composition (high visceral fat and low skeletal muscle mass) may benefit from closer clinical surveillance to prevent disease progression and reduce the risk of complications. ### 14. **Inflammatory Priming** - Pro-inflammatory mediators released by visceral fat sensitize the gallbladder, increasing the likelihood of exaggerated inflammatory responses when gallstones obstruct the bile duct. ### 15. **Metabolic Syndrome Link** - The study reinforces the connection between acute cholecystitis and metabolic syndrome conditions, such as hypertension, dyslipidemia, and insulin resistance. These systemic factors further contribute to the inflammatory and metabolic background of the disease. ### Conclusion: This retrospective cohort study challenges traditional views of acute cholecystitis as a purely local biliary event and highlights the importance of systemic metabolic and inflammatory factors. High visceral adiposity and low skeletal muscle mass are independent predictors of disease development, providing actionable insights for early risk stratification, preventive interventions, and a shift in clinical management toward addressing the broader metabolic-inflammatory context of acute cholecystitis.

LAMS for EUS-guided drainage of pancreatic fluid collections

Lumen-apposing metal stents (LAMS) have emerged as a highly effective tool for endoscopic ultrasound (EUS)-guided drainage of pancreatic fluid collections (PFCs), such as pseudocysts and walled-off necrosis. This systematic review and meta-analysis evaluated three commonly used types of LAMS: Axios, Nagi, and Spaxus, focusing on their efficacy, safety, and clinical performance. ### Key Findings: #### **Technical Success:** All three LAMS demonstrated exceptional technical success rates: - **Axios:** 97.7% - **Nagi:** 96.9% - **Spaxus:** 98.2% This indicates that the placement of the stents is highly reliable across all types. #### **Clinical Success:** Clinical success rates, which reflect effective resolution of the pancreatic fluid collections, were also strong: - **Axios:** 90.9% - **Nagi:** 88.5% - **Spaxus:** 93.5% This highlights that all three stents are effective in achieving the desired therapeutic outcomes. #### **Adverse Events (AEs):** Safety profiles varied significantly among the stents. - **Axios:** Highest rate of total adverse events (20.4%). - **Nagi:** Moderate rate of adverse events (13.8%). - **Spaxus:** Lowest rate of adverse events (7.6%). #### **Bleeding:** Bleeding complications were an important safety consideration, with rates differing across stent types: - **Axios:** Highest bleeding rate (7.0%). - **Nagi:** Moderate bleeding rate (3.8%). - **Spaxus:** Lowest bleeding rate (1.8%). Moderate-to-severe bleeding occurred across all stent types but was notably less frequent with Spaxus. #### **Stent Migration:** Stent migration was another safety concern: - **Axios:** Rare (2.8%). - **Nagi:** Most common (7.8%). - **Spaxus:** Least common (0.9%). #### **Need for Endoscopic Necrosectomy:** The need for additional procedures, such as endoscopic necrosectomy to remove necrotic debris, differed significantly: - **Axios:** Highest necrosectomy requirement (54.5%). - **Nagi:** Lower requirement (16%). - **Spaxus:** Comparable to Nagi (19.9%). #### **Impact of PFC Type:** - Patients with **walled-off necrosis** experienced more frequent adverse events compared to those with **pseudocysts**. This reflects the complexity and severity of walled-off necrosis compared to simpler pseudocysts. ### Overall Assessment: While all three LAMS options provide excellent efficacy for draining pancreatic fluid collections, their safety profiles differ meaningfully. The **Spaxus stent** demonstrated the most favorable balance of high success rates and low complications, including minimal bleeding, stent migration, and adverse events. However, the choice of stent may depend on patient-specific factors, the type of PFC (pseudocyst vs. walled-off necrosis), and procedural considerations. ### Clinical Implications: - **Axios** may be preferred for cases where high clinical success is paramount, although its higher rates of adverse events and bleeding should be considered. - **Nagi** offers a moderate safety profile but has a higher risk of stent migration. - **Spaxus** stands out for its excellent safety profile, making it a strong choice for minimizing complications while maintaining high efficacy. In conclusion, LAMS are a transformative advancement in the management of pancreatic fluid collections, offering minimally invasive, highly effective treatment options with differences in safety outcomes that warrant careful consideration.

EUS-guided GJ in acute pancreatitis related Gastric Outlet obstruction

Endoscopic Ultrasound-Guided Gastrojejunostomy (EUS-GJ) is an innovative, minimally invasive procedure that has gained traction as a treatment for gastric outlet obstruction (GOO) due to duodenal stenosis caused by acute pancreatitis. Acute pancreatitis can lead to inflammation and scarring in the duodenum, resulting in mechanical obstruction that prevents food passage from the stomach to the intestines. EUS-GJ offers a safe and effective alternative to traditional surgery for managing this condition. Below is a detailed explanation of why EUS-GJ is required and the technical challenges associated with the procedure: ### **Why EUS-GJ is Required** 1. **Minimally Invasive Alternative to Surgery**: - Traditional surgical gastrojejunostomy involves open or laparoscopic surgery, which can be associated with significant morbidity, longer recovery times, and increased risks in patients with acute pancreatitis. EUS-GJ provides a less invasive option that reduces these risks while achieving similar outcomes. 2. **Bypassing the Obstructed Duodenum**: - Acute pancreatitis-related duodenal stenosis can lead to severe symptoms such as nausea, vomiting, and an inability to tolerate oral intake. EUS-GJ bypasses the obstructed duodenum by creating a direct connection between the stomach and the jejunum (a part of the small intestine), restoring gastrointestinal continuity and allowing food passage. 3. **High Success Rates**: - The study reported a technical success rate of 92.3% and clinical success rate of 87.2%, demonstrating the effectiveness of EUS-GJ in relieving symptoms of GOO and improving oral intake. 4. **Durability and Long-Term Relief**: - Among patients with long-term follow-up (median 23 months), EUS-GJ showed good durability, with only a small number requiring reintervention. This makes it a reliable option for managing chronic GOO caused by acute pancreatitis. 5. **Low Complication Rates**: - Compared to surgical alternatives, EUS-GJ has a low rate of adverse events. In the study, only one significant complication (a gastrocolic fistula) was reported, and it did not lead to major clinical issues. ### **Technical Difficulties in EUS-GJ** EUS-GJ is a technically complex procedure that requires expertise in advanced endoscopy and familiarity with the use of lumen-apposing metal stents (LAMS). Some of the key technical challenges include: 1. **Anatomical Limitations**: - In some patients, the distance between the stomach and the small bowel may be too great, making it difficult to deploy the stent effectively. This was a limitation in three patients in the study, leading to procedural failure. 2. **Safe Puncture Window**: - The procedure relies on identifying a safe puncture site between the stomach and jejunum using endoscopic ultrasound. In cases where the anatomy does not allow for a clear puncture window, the procedure cannot be performed. 3. **Stent Deployment**: - Precise deployment of the lumen-apposing metal stent is critical for the success of the procedure. Misplacement or migration of the stent can lead to complications such as leakage, infection, or fistula formation. 4. **Risk of Adverse Events**: - Although the overall rate of complications is low, potential risks include bleeding, perforation, stent migration, or the formation of abnormal connections (e.g., gastrocolic fistula). These complications require careful monitoring and management. 5. **Need for Reintervention**: - In some cases, patients may require reintervention due to stent-related issues or recurrence of symptoms. The study reported that four patients needed reintervention during follow-up. 6. **Learning Curve**: - EUS-GJ requires advanced technical skills and experience with endoscopic ultrasound and stent placement. The procedure may be challenging for less experienced endoscopists, limiting its availability in some centers. ### **Conclusion** EUS-GJ is a groundbreaking procedure for managing gastric outlet obstruction caused by acute pancreatitis. It offers a safe, effective, and durable alternative to surgery, with high success rates and low complication rates. However, its technical complexity and anatomical limitations highlight the importance of careful patient selection and the need for skilled operators. As the procedure becomes more widely adopted, ongoing research and training will be critical to further improving outcomes and expanding its accessibility.

EUS-guided ethanol injections of small pancreatic NET

Endoscopic ultrasonography-guided ethanol injection (EUS-EI) is emerging as a promising, minimally invasive treatment for small pancreatic neuroendocrine tumors (PNENs), particularly for patients seeking alternatives to surgery. This approach involves using endoscopic ultrasound to guide the precise injection of ethanol into the tumor, inducing its ablation. The procedure has shown high efficacy in achieving complete tumor ablation and demonstrates a strong safety profile, with minimal risk of severe complications such as pancreatic fistulas or adverse events. Additionally, it appears to preserve pancreatic endocrine function, as most patients did not experience new or worsening diabetes after the procedure. EUS-EI offers a less invasive option compared to traditional surgical methods, making it a potentially suitable choice for patients with small, low-grade PNENs. This treatment is particularly beneficial for carefully selected patients who prioritize reduced recovery time and lower procedural risks.

Surveillance of Primary Sclerosing Cholangitis - EASL Guideline

Surveillance for Primary Sclerosing Cholangitis (PSC) is critical due to the high risk of hepatobiliary complications, including cholangiocarcinoma (CCA), gallbladder cancer, and liver failure, all of which significantly impact patient outcomes. The European Association for the Study of the Liver (EASL) provides guidelines to optimize the management of PSC, including recommendations for surveillance strategies aimed at early detection of complications and timely intervention. ### Why is Surveillance Necessary for PSC? 1. **High Risk of Cancer**: PSC is strongly associated with an elevated risk of cholangiocarcinoma, with an incidence of 0.5–1.5% per year in affected individuals. Additionally, the risk of gallbladder cancer and hepatocellular carcinoma (HCC) is also increased. 2. **Asymptomatic Progression**: PSC often progresses silently, with many patients remaining asymptomatic until advanced stages of disease or cancer development. Surveillance enables early detection of complications. 3. **Lack of Reliable Biomarkers**: There are no highly sensitive or specific tumor markers for PSC-associated cancers, such as CCA. CA19-9, a commonly used marker, has limited reliability and may lead to false positives or negatives. 4. **Improved Prognosis with Early Detection**: Early identification of disease progression or malignancy can lead to timely interventions, including liver transplantation, which may improve survival rates. ### EASL Guidelines on PSC Surveillance The EASL guidelines emphasize the importance of regular and structured surveillance for PSC patients to monitor for disease progression and associated complications. Key recommendations include: 1. **Regular Clinical Assessments**: - Patients should undergo regular clinical evaluations, including liver function tests, to monitor disease progression and assess for symptoms suggestive of complications such as biliary strictures or infections. 2. **Imaging Surveillance**: - **Magnetic Resonance Imaging (MRI) with Magnetic Resonance Cholangiopancreatography (MRCP)**: EASL recommends annual or biennial MRI/MRCP as the preferred imaging modality for PSC surveillance. This approach provides detailed visualization of the biliary tree and liver parenchyma, aiding in the detection of biliary strictures, CCA, or other abnormalities. - **Ultrasound**: While not as detailed as MRI/MRCP, regular ultrasound may be used to screen for gallbladder polyps or masses, which could indicate gallbladder cancer. 3. **Endoscopic Retrograde Cholangiopancreatography (ERCP)**: - ERCP should not be used routinely for surveillance due to its invasive nature and associated risks (e.g., pancreatitis, infections). However, it is recommended in cases where there are clinical or imaging findings suggestive of biliary obstruction, strictures, or malignancy. - In certain high-risk cases, scheduled ERCP with brush cytology and/or biopsies may be considered for more intensive surveillance, as highlighted in the study provided. 4. **Biomarker Monitoring**: - **CA19-9**: Serum CA19-9 levels may be measured annually, but clinicians should interpret results with caution due to the risk of false positives (e.g., due to cholangitis or other benign conditions) and false negatives (e.g., in patients who are non-secretors of CA19-9). - Other biomarkers, such as liver enzymes (alkaline phosphatase, bilirubin), should also be monitored regularly as they may indicate disease progression or complications. 5. **Colorectal Cancer Screening**: - PSC is closely linked with inflammatory bowel disease (IBD), particularly ulcerative colitis, which increases the risk of colorectal cancer. EASL recommends annual or biennial colonoscopy for PSC patients with IBD, starting at the time of PSC diagnosis, regardless of the duration of IBD. 6. **Gallbladder Surveillance**: - Gallbladder polyps >8 mm in size warrant surgical removal due to the high risk of malignancy in PSC patients. - Annual ultrasound imaging is recommended to monitor for gallbladder abnormalities. 7. **Liver Transplantation Consideration**: - Surveillance plays a critical role in identifying patients who may benefit from liver transplantation. Early referral for transplantation evaluation is recommended for patients with decompensated cirrhosis, recurrent cholangitis, or early-stage CCA. ### Insights from the Study in Context The study you provided highlights the potential benefits of scheduled ERCP as a surveillance strategy for PSC patients. While EASL guidelines currently favor MRI/MRCP as the primary imaging modality for routine surveillance due to its non-invasive nature, the study suggests that scheduled ERCP combined with individualized risk assessment may provide better outcomes in terms of earlier detection of disease progression and reduced cumulative incidence of adverse events. However, the invasive nature and potential complications of ERCP mean that its routine use for all PSC patients is not currently endorsed by EASL; instead, it is reserved for cases with specific clinical indications. ### Summary EASL guidelines prioritize non-invasive imaging (e.g., MRI/MRCP) and regular biomarker monitoring for PSC surveillance, while reserving invasive procedures like ERCP for specific clinical scenarios. The goal of surveillance is to detect complications such as cholangiocarcinoma, biliary strictures, and liver decompensation early, enabling timely intervention and improving long-term outcomes. The study findings suggest that scheduled ERCP may offer additional benefits in certain high-risk patients, which could inform future updates to surveillance guidelines.

Optimal timing for LAMS removal after EUS-guided drainage of PFC

The optimal timing for lumen-apposing metal stent (LAMS) removal after EUS-guided drainage of pancreatic fluid collections (PFCs) does not necessarily depend on a fixed timeline, such as early removal within 3–4 weeks. A systematic review and meta-analysis of 8 studies involving 1820 patients found no significant difference in adverse events (AEs) between early and late stent removal. The pooled risk ratio for AEs was 1.03, indicating comparable safety outcomes regardless of removal timing. Additionally, a sensitivity analysis using a strict 4-week cut-off confirmed these findings. Prolonged stent placement has been associated with complications like bleeding, buried stents, and infection, but early removal does not appear to reduce these risks. The study suggests that removal timing should be guided by clinical judgment rather than a universal early-removal policy. Factors such as patient stability, imaging findings, and individual circumstances should dictate the decision, supporting a case-by-case approach rather than adhering to a rigid timeline.

Portal versus peripheral circulating tumor cells in PDAC

The study you referenced investigates the differences between portal and peripheral circulating tumor cells (CTCs) in pancreatic ductal adenocarcinoma (PDAC) and their prognostic value. Here’s a detailed breakdown of the findings and their implications: ### Background: - Pancreatic tumors drain into the portal venous system before entering systemic circulation. This suggests that CTCs collected from the portal vein may better reflect tumor biology, early micrometastasis, and aggressiveness compared to CTCs collected from peripheral blood. - The study aimed to determine whether portal vein CTCs provide superior prognostic information compared to peripheral CTCs in patients with stage I–III PDAC. ### Methodology: - **Patient Cohort**: A prospective cohort of 35 patients with stage I–III PDAC was studied. - **Blood Sampling**: - **Portal Venous Blood**: Obtained using endoscopic ultrasound–guided techniques. - **Peripheral Blood**: Drawn conventionally. - **CTC Identification**: CTCs were detected using antibodies targeting EpCAM and mucin-1. - **Analysis**: CTC counts were correlated with tumor characteristics, survival outcomes, and prognostic significance. ### Key Findings: 1. **Detection Rates**: - Portal venous blood showed a higher detection rate of CTCs (94.3%) compared to peripheral blood (82.9%). - This indicates that portal blood more reliably captures CTCs, likely because pancreatic tumors drain directly into the portal venous system. 2. **Correlation with Tumor Characteristics**: - Portal CTC levels strongly correlated with aggressive tumor features, including: - Tumor size ≥5 cm. - Vascular invasion. - Lymph node metastasis. - Stage III disease. - Peripheral CTCs did not show similar associations with these aggressive tumor characteristics. - This suggests that portal CTCs better reflect the true biology and local spread of the tumor. 3. **Prognostic Value**: - **Portal CTCs**: - Patients with portal CTC counts ≥8 had significantly shorter survival (median of 6.1 months) compared to those with counts <8 (19 months). - **Peripheral CTCs**: - Patients with peripheral CTC counts ≥3 also had shorter survival (4.6 months) compared to those with counts <3 (14.2 months). - Both portal and peripheral CTCs were independent predictors of mortality in multivariable analyses. - However, portal CTCs were more effective in capturing tumor aggressiveness and locoregional metastatic potential. 4. **Survival Outcomes**: - Elevated CTC counts in both portal and peripheral blood were associated with worse survival. - However, portal CTCs provided stronger prognostic information, making them a more powerful biomarker for early-stage to locally advanced PDAC. ### Clinical Implications: - **Prognostic Biomarker**: Portal CTCs are a more reliable and robust biomarker for predicting prognosis in PDAC compared to peripheral CTCs. - **Early Detection of Aggressiveness**: Portal CTCs may help identify patients with aggressive tumor features and early micrometastasis, allowing for better stratification and treatment planning. - **Potential for Personalized Therapy**: Monitoring portal CTC levels could guide treatment decisions, such as the need for more aggressive therapy in patients with high portal CTC counts. ### Conclusion: - While both portal and peripheral CTCs predict worse survival outcomes in PDAC, portal CTCs are superior in capturing tumor aggressiveness, locoregional spread, and early micrometastasis. This positions portal venous CTCs as a more powerful and clinically relevant prognostic biomarker for patients with stage I–III PDAC.